Loading
The first ADC to extend life in ovarian cancer, for the roughly one-third of tumours with high folate receptor alpha.
MIRASOL, also GOG-3045, trial NCT04209855 sponsored by ImmunoGen, now AbbVie, and published in the New England Journal of Medicine in 2023, produced the first antibody-drug conjugate to extend life in ovarian cancer, for the roughly one-third of platinum-resistant tumours with high folate receptor alpha expression. It randomised 453 women with one to three prior lines to mirvetuximab soravtansine or chemotherapy, met its primary progression-free survival endpoint and improved overall survival, leading to full approval in March 2024; ocular toxicity is frequent but reversible with eye-drop prophylaxis. OnCo links it to ovarian cancer, antibody-drug conjugates, folate receptor alpha, mirvetuximab soravtansine, Kathleen N. Moore, Ursula A. Matulonis and the GOG Foundation. Whether the drug can move into platinum-sensitive or maintenance settings is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
453 enrolled.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ursula A. Matulonis, Mirvetuximab soravtansine, Platinum-resistant ovarian cancer, Antibody-drug conjugate (ADC).
Shares Kathleen N. Moore, Folate receptor alpha, Mirvetuximab soravtansine, Antibody-drug conjugate (ADC).
Shares Mirvetuximab soravtansine, Platinum-resistant ovarian cancer, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer, Folate receptor alpha, Mirvetuximab soravtansine, Platinum-resistant ovarian cancer.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Folate receptor alpha, Mirvetuximab soravtansine, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/